Identity
Adipotide is an experimental peptidomimetic designed to target blood vessels in white fat. Its animal weight-loss findings do not establish a safe human obesity treatment.
Nonhuman-primate experiment; not a human product specification.
Peptide library
Adipotide (FTPP)
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Weight loss in obese monkeys is a translational signal, but the same development work raises renal toxicity concerns. Reversibility in animals does not establish an acceptable human treatment window.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Nonhuman primates, including obese rhesus monkeys; not a controlled human obesity trial.
What the sources found
Obese rhesus monkeys lost weight, but kidney tubular injury and altered renal function were observed. Animal reversibility does not establish human safety.
Nonhuman-primate experiment; not a human product specification.
What remains unknown
A targeted source review, not a complete clinical monograph. Product stability, long-term safety, interactions and jurisdiction-specific authorization require further verification. Research findings do not validate commercial vials.
How it works
The construct combines an adipose-vascular targeting segment with a cell-death-promoting segment. The primate study examined fat loss and metabolic changes.
The construct combines an adipose-vascular targeting segment with a cell-death-promoting segment. The primate study examined fat loss and metabolic changes.
Nonhuman-primate experiment; not a human product specification.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- Renal tubular injury and functional changes occurred in the animal study; human incidence and reversibility are not established.
Contraindications
- The reviewed evidence does not establish a complete clinical contraindication profile.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
Claim-by-claim evidence
Mechanism
The construct combines an adipose-vascular targeting segment with a cell-death-promoting segment. The primate study examined fat loss and metabolic changes.
Nonhuman-primate experiment; not a human product specification.
Findings
Obese rhesus monkeys lost weight, but kidney tubular injury and altered renal function were observed. Animal reversibility does not establish human safety.
Nonhuman-primate experiment; not a human product specification.
Dose
The primate experiment is not a human dosing protocol. No human regimen is supplied.
Nonhuman-primate experiment; not a human product specification.
Pharmacokinetics
No validated human elimination half-life was established by the cited primate study.
Nonhuman-primate experiment; not a human product specification.
References
Barnhart et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011.
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.